Genentech, the biotech subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other preventive option for patients with this problem.
News
- FDA OKs new therapy for some hemophilia patients
- US health agency to crack down on risky stem cell offerings
It also laid out a process for speeding up the review of promising cell and genetic therapies long sought by drug and biotech companies in the field.
- Search for Novel Biomarkers Indicating Early Cardiovascular Disease Risk Wins Funding to ...
Newswise — San Antonio, Texas (November 15, 2017) – Texas Biomedical Research Institute scientists have been granted funding from the National ...
- Here's Why This Analyst Is Not Counting Immunomedics, Inc. (IMMU) Out of Approval in mTNBC ...
... abstracts surfaced at the yearly San Antonio Breast Cancer Symposium (SABCS), ... Wall Street's initial word on this biotech player goes to the bulls, ...
- INVO Bioscience Reports Third Quarter 2017 Financial Results
MEDFORD, MA / ACCESSWIRE / November 14, 2017 / INVO Bioscience, ... Scientific Congress & Expo in San Antonio, Texas in the end of October.